Industry Educational Session -Reimagining Intensive Chemotherapy for AML: Utilising an MDT approach to optimise patient outcomes. - Sponsored by Pfizer
Tracks
-
| Monday, April 28, 2025 |
| 1:30 PM - 2:15 PM |
| M4 |
Details
Join leading experts Dr. Eleni Tholouli, Dr. Rowena Thomas-Dewing, Consultant Pharmacist Elizabeth Davies and Clinical Nurse Specialist Joanne Preston for an in-depth MDT panel discussion on the management of Acute Myeloid Leukaemia (AML). This educational session will explore the essential role of the MDT and its impact on clinical practice, while delving into critical topics such as addressing system capacity challenges and implementing intensive chemotherapies in district general hospitals. Drawing on their combined approach and clinical experience, the session provides actionable insights into integrating an MDT approach into regional practice to enhance patient outcomes.
Speaker
Ms. Elizabeth Davies
Consultant Pharmacist
Manchester University NHS Foundation Trust
- honorary senior lecturer at the University of Manchester where she teaches pharmacist undergraduates and NHS clinical scientist trainees.
Joanne Preston
Manchester Royal Infirmary
- Clinical Nurse Specialist - Prehabilitation at Manchester Royal Infirmary
Dr Eleni Tholouli
Consultant Haematologist and Director of Adult Stem Cell Transplant and Cellular Therapies Unit
Manchester Royal Infirmary
- PhD at Manchester University investigating prognostic molecular markers in acute myeloid leukaemia
Dr. Rowena Thomas-Dewing
- Consultant Haematologist at Salford Royal Hospital
